Insulin resistance syndrome. Description, pathogenesis, and management

Area of Science:

• Endocrinology
• Cardiovascular Medicine
• Metabolic Syndrome

Background:

• Insulin resistance syndrome presents multiple cardiovascular disease risk factors: insulin resistance, dyslipidemia, hypertension, obesity, and impaired hemostasis.
• Type 2 diabetes patients often exhibit these risk factors, increasing cardiovascular morbidity and mortality.
• Current management involves antihypertensives, lipid-lowering, and antihyperglycemic agents.

Purpose of the Study:

• To evaluate the benefits of thiazolidinediones (TZDs) in managing insulin resistance syndrome in type 2 diabetes.
• To explore the potential of early TZD intervention for cardiovascular risk reduction.
• To assess the efficacy of combination therapy with TZDs and biguanides for glycemic control.

Main Methods:

• Review of pharmacological actions of thiazolidinediones (TZDs).
• Analysis of TZD effects on insulin sensitivity, glucose, and lipid metabolism.
• Evaluation of combination therapy outcomes with TZDs and biguanides.

Main Results:

• TZDs directly improve insulin resistance, lowering plasma glucose and insulin levels.
• TZDs promote beneficial body fat redistribution and exert anti-inflammatory effects on vascular endothelium.
• Combination therapy with TZDs and biguanides demonstrates significant benefits in glycemic control and complication prevention.

Conclusions:

• Early implementation of TZDs can substantially benefit type 2 diabetes patients by addressing insulin resistance.
• Combination therapy, particularly TZD and biguanide, offers a promising strategy for managing type 2 diabetes and its associated cardiovascular risks.
• TZDs play a crucial role in improving metabolic parameters and potentially delaying diabetes-related complications.